［1］BRAY F,LAVERSANN M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(03):229-263.
［2］刘梦梦,卢秀霞,杨静，等.软组织肉瘤的靶向治疗药物研究进展［J］.肿瘤综合治疗电子杂志,2021,7(04):13-18.
LIU MM,LU XX,YANG J,et al.Advances in targeted therapy drugs of soft tissue sarcoma［J］.Journal of Multidisciplinary Cancer Management (Electronic Version),2021,7(04):13-18.
［3］D' ADAMO RD.Appraising the current role of chemotherapy for the treatment of sarcoma［J］.Seminars in Oncology,2011,38(suppl_S3):S19-S29.
［4］BURKHARD MA,BERCLAZ LM,DI GD,et al.Current therapeutic standards in advanced soft tissue sarcomas［J］.Deut Med Wochenschr,2024,149(6):303-307.
［5］崔广华,杨宇.安罗替尼在晚期恶性肿瘤治疗中的研究进展［J］.现代肿瘤医学,2022,30(16):3032-3036.
CUI GH,YANG Y.Research progress of anlotinib in the treatment of advanced malignant tumors［J］.Modern Oncology,2022,30(16):3032-3036.
［6］SMOLLE MA,SZKANDERA J,ANDREOU D,et al.Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis-a systematic literature review［J］.EFORT Open Reviews,2020,5(11):799-814.
［7］XIE L,SUN X,XU J,et al.The efficacy and safety of vincristine,irinotecan and anlotinib in epithelioid sarcoma［J］.BMC Cancer,2024,24(1):172.
［8］ ZHENG A,LIU J,LIU Z,et al.Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy［J］.J Cancer Res Clin,2024,150(2):58.
［9］TANG L,YU W,WANG Y,et al.Anlotinib inhibits synovial sarcoma by targeting GINS1:a novel downstream target oncogene in progression of synovial sarcoma［J］.Clinical and Translational Oncology,2019,21(12):1624-1633.
［10］CHI Y,YAO Y,WANG S,et al.Anlotinib for metastasis soft tissue sarcoma:A randomized,double-blind,placebo-controlled and multi-centered clinical trial［J］.Journal of Clinical Oncology,2018,36(15_suppl):11503.
［11］WANG ZM,ZHUANG RY,GUO X,et al.Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma:an open-label,single-arm,phase 2 trial［J］.Clinical Cancer Research,2022,28(24):5290-5296.
［12］刘佳勇,樊征夫,李舒,等.盐酸安罗替尼胶囊治疗晚期软组织肉瘤Ⅱb期多中心临床试验的单中心数据分析［J］.中国肿瘤临床,2018,45(20):1066-1070.
LIU JY,FAN ZF,LI S,et al.Anlotinib hydrochloride capsules for advanced soft tissue sarcoma:single-center data analysis of a stageⅡb multicenter clinical trial［J］.Chinese Journal of Clinical Oncology,2018,45(20):1066-1070.
［13］ MI YJ,LLIANG YJ,HUANG HB,et al.Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters［J］.Cancer Research,2010,70(20):7981-7991.
［14］ HUANG H,ZHANG H,CAO B.A study protocol for an open-label,single-arm,single-center phase Ⅰ clinical study on tolerability,safety,and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma［J］.Thorac Cancer,2024,15(5):427-433.
［15］LIU XY,XU J,LI F,et al.Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma:Chinese cohort data from NCT03121846［J］.Biomedicine & Pharmacotherapy,2020,122(C):109587
［16］叶挺,李天宇,范丽,等.应用阿帕替尼治疗进展期软组织肉瘤的临床效果与安全性评估［J］.骨科临床与研究杂志,2023,8(02):91-98.
YE T,LI TY,FAN L,et al.Efficacy and safety of apatinib in the treatment of advanced soft tissue sarcoma［J］.Journal of Clinical Orthopedics and Research,2023,8(02):91-98.
［17］YU WX,ZHANG HM,CHEN J,et al.Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma:a multicenter,phase 2 trial［J］.Annals of Translational Medicine,2022,10(18):981
［18］LONG ZY,HUANG MQ,LIU KT,et al.Assessment of efficiency and safety of apatinib in advanced bone and soft tissue sarcomas:A systematic review and meta-analysis［J］.Frontiers in Oncology,2021,11:662318.
［19］YAO WT,WU FX,CAI QQ,et al.Efficacy and safety of apatinib in advanced sarcoma:an open-label,nonrandomized,single-center study of 45 patients［J］.Anti-Cancer Drugs,2019,30(7):749-756.
［20］黄丹丽,贾晶晶,吴茂锋.培唑帕尼在肿瘤临床治疗应用的研究进展［J］.中国处方药,2021,19(07):18-20.
HUANG DL,JIA JJ,WU MF.Progress in the application of pazopanib in the treatment of different tumor［J］.Journal of China Prescription Drug,2021,19(07):18-20.
［21］CHELLAPPAN DK,CHELLIAN J,NG ZY,et al.The role of pazopanib on tumour angiogenesis and in the management of cancers:A review［J］.Biomedicine & Pharmacotherapy,2017,96:768-781.
［22］CHO HJ,YUN KH,SHIN SJ,et al.Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas:a phase Ⅱ trial［J］.Nat Commun,2024,15(1):685.
［23］BILICI A,KOCA S,KARAAGAC M,et al.Real-world outcomes of pazopanib in metastatic soft tissue sarcoma:a retrospective Turkish oncology group (TOG) study［J］.Journal of Cancer Researchand Clinical Oncology,2023,149(11):8243-8253.
［24］KAWAI A,ARAKI N,HIRAGA H,et al.A randomized,double-blind,placebo-controlled,phase Ⅲ study of pazopanib in patients with soft tissue sarcoma:results from the Japanese subgroup［J］.Japanese Journal of Clinical Oncology,2016,46(3):248-253.
［25］MARTIN-BROTO J,STACCHIOTTI S,LOPEZ-POUSA A,et al.Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour:a multicentre,single-arm,phase 2 trial［J］.Lancet Oncology,2019,20(1):134-144.
［26］NAKAMURA T,MATSUMINE A,KAWAI A,et al.The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma:A Japanese Musculoskeletal Oncology Group (JMOG) study［J］.Cancer,2016,122(9):1408-1416.
［27］MOCHIZUKI T,IKEGAMI M,AKIYAMA T.Factors predictive of second-line chemotherapy in soft tissue sarcoma:An analysis of the National Genomic Profiling Database［J］.Cancer Sci,2024,115(2):575-588.
［28］ UGUREL S,MENTZEL T,UTIKAL J,et al.Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans:A multicenter phase Ⅱ DeCOG trial with long-term follow-up［J］.Clinical Cancer Research,2014,20(2):499-510.
［29］ LEMM D,MUEGGE LO,HOEFFKEN K,et al.Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans-a case report［J］.Oral & Maxillofacial Surgery,2008,12(4):209-213.
［30］ ONO T,NOGUCHI R,OSAKI J,et al.Establishment and characterization of NCC-DFSP5-C1:a novel patient-derived dermatofibrosarcoma protuberans cell line［J］.Hum Cell,2024,37(3):854-864.
［31］RUTKOWSKI P,KLIMCZAK A,LUGOWSKA I,et al.Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate-the impact of fibrosarcomatous transformation［J］.European Journal of Surgical Oncology,2017,43(6):1134-1141.
［32］WANG CM,LUO ZG,CHEN J,et al.Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate:an analysis on 22 Chinese patients［J］.Medicine (Baltimore),2015,94(17):e773.
［33］CHUGH R,WATHEN JK,PATEL SR,et al.Efficacy of imatinib in aggressive fibromatosis:Results of a phase Ⅱ multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial［J］.Clinical Cancer Research,2010,16(19):4884-4891.
［34］金小虎,葛一涵,赵毅.血管内皮生长因子与乳腺癌的研究进展［J］.中国肿瘤临床与康复,2020,27(12):1533-1536.
JIN XH,GEI YH,ZHAO Y.Research progress of vascular endothelial growth factor and breast cancer［J］.Chinese Journal of Clinical Oncology and Rehabilitationehabil,2020,27(12):1533-1536.
［35］HU Y,LUO Z,CAI S,et al.Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma［J］.Scand J Gastroentero,2024,59(6):730-736.
［36］D'ADAMO DR,DICKSON MA,KEOHAN ML,et al.A phase Ⅱ trial of sorafenib and dacarbazine for leiomyosarcoma,synovial sarcoma,and malignant peripheral nerve sheath tumors［J］.The Oncologist,2019,24(6):857-863.
［37］QUE Y,LIANG Y,ZHAO JJ,et al.Treatment-related adverse effects with pazopanib,sorafenib and sunitinib in patients with advanced soft tissue sarcoma:a pooled analysis［J］.Cancer Management & Research,2018,10:2141-2150.
［38］AGULNIK M,ATTIA S.Growing role of regorafenib in the treatment of patients with sarcoma［J］.Targeted Oncology,2018,13(4):417-422.
［39］BLAY JY,DUFFAUD F,GEORGE S,et al.Regorafenib for the treatment of sarcoma［J］.Current Treatment Options in Oncology,2022,23(11):1477-1502.
［40］SCHOFFSKI P,WOZNIAK A,STACCHIOTTI S,et al.Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations:European organization for research and treatment of cancer phase Ⅱ trial 90101 ' CREATE' ［J］.Annals of Oncology,2017,28(12):3000-3008.
［41］ XU XJ,LI H,PENG K,et al.ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib:A case report［J］.Oncology Letters,2019,17(2):2370-2376.
［42］XIE L,XU J,SUN X,et al.Apatinib for advanced osteosarcoma after failure of standard multimodal therapy:an open label phase Ⅱ clinical trial［J］.Oncologist,2019,24:e542-e550.
［43］RAMSDEN JD.Angiogenesis in the thyroid gland［J］.J Endocrinol,2000,166:475-480.
［44］郭卫,谢璐.抗血管生成酪氨酸激酶抑制剂联合化学药物治疗骨与软组织肉瘤的安全管理专家共识［J］.中华骨与关节外科杂志,2022,15(12):902-913.
GUO W,XIE L.Expert consensus on the safety management of anti-angiogenic tyrosine kinaseinhibitors in combination with chemotherapy for sarcoma treatment［J］.Chinese Journal of Bone and Joint,2022,15(12):902-913.
［45］GRIGNANI G,PALMERINI E,FERRARESI V,et al.Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment:a nonrandomised phase 2 clinical trial［J］.Lancet Oncology,2015,16(1):98-107.
［46］MIR O,BRODOWICZ T,ITALIANO A,et al.Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC):a randomised,double-blind,placebo controlled,phase 2 trial［J］.Lancet Oncology,2016,17(12):1732-1742.
［47］ WANG X,NAKANO K,SHIGA T,et al.Assessment of pazopanib-related heart failure in patients with advanced soft tissue sarcoma-a single institute analysis［J］.Circ J,2024,88(2):228-233.
［48］许婕.抗血管生成酪氨酸激酶抑制剂联合免疫检查点抑制剂治疗肉瘤药物安全管理共识［J］.中国骨与关节杂志,2023,12(07):526-532.
XU J.Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors incombination with mmune checkpoint inhibitors for sarcoma treatment［J］.Chinese Journal of Bone and Joint,2023,12(07):526-532.
［49］叶挺,范丽,曹如波,等.VCD/IE方案联合阿帕替尼治疗化疗失败进展期尤因肉瘤的回顾性研究［J］.中国肿瘤临床,2023,50(03):125-129.
YE T,FAN L,CAO RB,et al.A retrospective study on VCD/IE regimen combined with apatinib for advanced Ewing sarcoma unresponsive to chemotherapy［J］.Chinese Journal of Clinical Oncology,2023,50(03):125-129.
［50］申宇翔,张超,韩秀鑫,等.安罗替尼联合阿霉素和异环磷酰胺治疗软组织肉瘤肺转移的疗效及安全性分析［J］.中国肿瘤临床,2023,50(03):117-124.
SHEN YX,ZHANG C,HAN XX,et al.Efficacy and safety of anlotinib combined with adriamycin ifosfamide in the treatment of lung metastasis of soft tissue sarcoma［J］.Chinese Journal of Clinical Oncology,2023,50(03):117-124.
［51］孙艳芳,朱卫红.依维莫司联合索拉菲尼治疗复发难治性骨肉瘤的疗效及对血清TSGF、VEGF、Ras、ErbB3水平的影响［J］.现代肿瘤医学,2019,27(13):2379-2383.
SUN YF,ZHU WH.Efficacy of everolimus combined with sorafenib in the treatment of relapsed and refractory osteosarcoma and its effect on serum TSGF，VEGF，Ras and ErbB3 levels［J］.Modern Oncology,2019,27(13):2379-2383.
［52］王林,高嵩涛,王志斌,等.手术切除联合术中放疗治疗四肢复发性软组织肉瘤的安全性及近期疗效［J］.现代肿瘤医学，2022,30(20):3747-3752.
WANG L,GAO ST,WANG ZB,et al.Safety and short-term efficacy of surgical resection combined with intraoperative radiotherapy in the treatment of recurrent soft tissue sarcoma of the extremities［J］.Modern Oncology,2022,30(20):3747-3752.